he prevalence rates of
methicillin-resistant
Staphylococcus aureus (MRSA) infections
has been linked to the quality of care, and are
considered the benchmark for hospital infection control practices. As
the therapeutic management of MRSA infections is very different from
those due to methicillin-sensitive Staphylococcus aureus (MSSA),
there is a need to study risk factors associated with acquisition of
MRSA which will guide the empirical antibiotic choices. A delay in
appropriate initial antibiotic choice can increase mortality and
morbidity associated with these infections, especially in intensive care
settings. An understanding of these factors would help to generate
evidence not only to decide the choice of empirical antibiotics but
would also help in deciding strategies to control the transmission and
spread of MRSA within the hospital. Most of the studies available on
risk factors have been conducted in adult settings; similar studies in
children are lacking.
Emergence of the fact that community acquired MRSA
clones are different from healthcare-associated MRSA has disproved that
hospitalization is the sole factor for MRSA, and also indicates that the
risk factors are also present in the community which select out the
resistant Staphyloccocus aureus strains.
In the study published in the present issue of
Indian Pediatrics, Senthilkumar and colleagues [1] have studied the
clinical predictors and risk factors associated with MRSA in children.
They conclude that clinical characteristics of MRSA do not differ from
MSSA infections. Further, they report that MRSA is more likely to be
isolated from children with high total leucocyte count. In their study,
80% of the total MRSA isolates were community acquired MRSA. It would
have been useful if the authors had provided more clear definitions of
community acquired MRSA, healthcare-associated MRSA and
healthcare-associated CO phenotype in their paper.
Overall, healthcare-associated MRSA still remains
more prevalent, and is also resistant to more classes of antibiotics,
therefore limiting the therapeutic options. Healthcare-associated MRSA
is more commonly responsible for blood stream infections (BSI) and skin
and soft tissue infections (SSTI). A study conducted in three teaching
hospitals in North India [2] – to understand the risk factors associated
with SSTI due to MRSA – reported an overall prevalence of MRSA causing
SSTIs as 31.2%. A stepwise multiple logistic regression analysis
adjusting for the differences among the hospitals indicated that factors
like longer duration of hospital stay, presence of dermatosis,
osteomyelitis and recent use of aminoglycosides and clindamycin were
significantly associated with MRSA-SSTIs.
In a study evaluating risk factors for intensive care
unit (ICU) acquired BSI due to MRSA [3], duration of hospitalization in
ICU, simultaneous MRSA colonization in another patient in the ICU, prior
use of antibiotics, and presence of central line were reported as
independent risk factors. Duration of hospital stay has emerged as a
common risk factor for acquiring not only MRSA but also multi-drug
resistant (MDR) gram negative bacteria from most of the published
literature. In turn, healthcare-associated infections determine the
length of hospital stay [4]. The presence of skin lesions or infections
or dermatosis can also be related to increased chances of colonization
with MRSA, and more likelihood of prior antibiotic therapy. In a
multicenter retrospective cohort study [5], a significant dose-effect
relationship was seen between the prescription of antimicrobial drugs
and MRSA infections.
There are studies that suggest a significant
association of MRSA colonization as risk factor for subsequent
infections with MRSA in hospitals as well as community. This is the
reason that decolonization with chlorhexidine has been used as a
strategy to prevent MRSA infections in hospital settings [6]. Other
studies have also shown that nasal carriage is a risk factor in also in
community acquired as well as healthcare-associated MRSA [7].
Finally, it is the local epidemiology and resistance
profile of bacteria causing infections that is important while making
the choice of empirical antibiotics. Therefore, studies on risk factors
or prevalence of MRSA infections must have clear definitions for
community acquired MRSA and healthcare-associated MRSA, and also look at
the antimicrobial susceptibility profiles. Community acquired MRSA have
more options of antibiotics, being susceptible to clindamycin,
fluoroquinolones, cotrimoxazole and erythromycin, unlike
healthcare-associated MRSA where vancomycin and linezolid are the
limited choices [8]. It is also important to correctly identify MSSA
from MRSA as beta-lactams have superior activity against S. aureus
and therefore vancomycin should be avoided if MSSA is confirmed. The
need to judiciously use vancomycin is not only to prevent emergence to
vancomycin-intermediate S. aureus or vancomycin-resistant S.
aureus but also to reduce the collateral damage in tertiary care
settings where emergence of vancomycin-resistant enterococcus is linked
to the use of vancomycin [9].
To be able to effectively control the spread of MRSA
in any setting, it is imperative to know its risk factors and the modes
of spread. There is now enough evidence that transmission by hands
remains the most important method for acquisition and spread of MRSA in
hospitals [10]. Strategies focusing on hand hygiene and use of standard
precautions have shown a significant reduction in MRSA transmission
[10]. This will go a long way in reducing the length of hospital stay,
antibiotic use and the emergence of multidrug resistant bacteria.
1. Senthilkumar K, Biswal N, Sistla S. Risk factors
associated with methicillin-resistant Staphylococcus aureus
infection in children. Indian Pediatr. 2015;52:31-3.
2. Gadepalli R, Dhawan B, Kapil A, Sreenivas V, Jais
M, Gaind R, et al. Clinical and molecular characteristics of
nosocomial meticillin-resistant Staphylococcus aureus skin and soft
tissue isolates from three Indian hospitals. J Hosp Infect.
2009;73:253-63.
3. Oztoprak N, Cevik MA, Akinci E, Korkmaz M, Erbay
A, Eren SS, et al. Risk factors for ICU-acquired methicillin-resistant
Staphylococcus aureus infections. Am J Infect Control. 2006;34:1-5.
4. Gupta A, Kapil A, Lodha R, Kabra SK, Sood S,
Dhawan B, et al. Burden of healthcare-associated infections in a
paediatric intensive care unit of a developing country: A single centre
experience using active surveillance. J Hosp Infect. 2011;78:323-6.
5. Catry B, Latour K, Jans B, Vandendriessche S,
Preal R, Mertens K, et al. Risk factors for methicillin resistant
Staphylococcus aureus: a multi-laboratory study. PLoS One.
2014;9:e89579.
6. Huang SS, Septimus E, Kleinman K, Moody J, Hickok
J, Avery TR, et al; CDC Prevention Epicenters Program; AHRQ
DECIDE Network and Healthcare-Associated Infections Program. Targeted
versus universal decolonization to prevent ICU infection. N Engl J Med.
2013;368:2255-65.
7. von Eiff C, Becker K, Machka K, Stammer H, Peters
G. Nasal carriage as a source of Staphylococcus aureus bacteremia. Study
Group. N Engl J Med. 2001;344:11-6.
8. Dhawan B, Rao C, Udo EE, Gadepalli R, Vishnubhatla
S, Kapil A. Dissemination of methicillin-resistant Staphylococcus aureus
SCCmec type IV and SCCmec type V epidemic clones in a tertiary hospital:
Challenge to infection control. Epidemiol Infect. 2014:1-11.
9. Dhawan B, Gadepalli R, Rao C, Kapil A, Sreenivas
V. Decreased susceptibility to vancomycin in meticillin-resistant
Staphylococcus aureus: A 5 year study in an Indian tertiary hospital. J
Med Microbiol. 2010;59:375-6.
10. van Velzen EV, Reilly JS, Kavanagh K, Leanord A,
Edwards GF, Girvan EK, et al. A retrospective cohort study into
acquisition of MRSA and associated risk factors after implementation of
universal screening in Scottish hospitals. Infect Control Hosp Epidemiol.
2011;32:889-96.